The effects of the 5-hydroxytryptamine (5HT3) receptor antagonist ICS 205-930 in the carcinoid syndrome
| Autor: | J. V. Anderson, H. J. F. Hodgson, S.R. Bloom, E. M. Alstead, J. A. Morris, M. O. Coupe |
|---|---|
| Rok vydání: | 2007 |
| Předmět: |
Adult
Diarrhea Male Drug medicine.medical_specialty Pathology Indoles media_common.quotation_subject Tropisetron Symptomatic treatment Gastroenterology Internal medicine medicine Humans Pharmacology (medical) Aged Malignant Carcinoid Syndrome media_common Hepatology business.industry Middle Aged medicine.disease Open study 5HT3 Receptor Antagonist Injections Intravenous Female Serotonin Antagonists business Carcinoid syndrome |
| Zdroj: | Alimentary Pharmacology & Therapeutics. 2:167-172 |
| ISSN: | 1365-2036 0269-2813 |
| DOI: | 10.1111/j.1365-2036.1988.tb00684.x |
| Popis: | SUMMARY Therapy for diarrhoea associated with the carcinoid syndrome is often unsatisfactory. In an open study ICS 205-930 (Sandoz Limited), a novel 5HT3-antagonist, controlled diarrhoea in five of six patients studied. This drug may be a useful advance in the symptomatic treatment of the carcinoid syndrome. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text